drugset
drugset / Trial / NCT00536978

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

NCT00536978 ↗

Phase 2 Completed 22 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

Primary objective: * To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen. Secondary objective: * To determine the efficacy (disease-free-survival) of this strategy.

Timeline

Start
2007-09
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Background Alemtuzumab Monoclonal antibody 15 mg Intravenous
Background Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Background Cytarabine Small molecule 100 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Melphalan Small molecule 100 mg/m2 Intravenous
Background Methotrexate Small molecule 5 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 1000 mg/m2 Intravenous
Background Tacrolimus Small molecule 0.03 mg/kg Intravenous
Background carmustine Small molecule 300 mg/m2 Intravenous

Indications

leukemia lymphoma